RaQualia Pharma

RaQualia Pharma Inc. details its drug pipeline.

The company provides an update on its Q2 earnings briefing for fiscal 2023 (16th term).

RaQualia Pharma Inc. announces the launch of tegoprazan, a treatment for gastroesophageal reflux disease, in Mexico.

RaQualia Pharma Inc. subsidiary Oxford Cannabinoid Technologies receives approval in the UK to conduct a phase I clinical trial for a CB2 receptor agonist.

RaQualia Pharma Inc. reports that Nagoya University-led clinical research on tamibarotene for pancreatic and urothelial cancers is selected for AMED’s clinical research promotion program.

RaQualia Pharma Inc. announces personnel changes at its subsidiaries.

RaQualia Pharma Inc. provides details about its fiscal 2022 (15th term) earnings explanation meeting.

RaQualia Pharma Inc. shares recruitment information.

RaQualia Pharma Inc. outlines its corporate governance structure.

RaQualia Pharma Inc. provides information about its executives.

RaQualia Pharma Inc. shares a message from its CEO.

RaQualia Pharma Inc. shares corporate information.

RaQualia Pharma Inc. provides investor relations contact details.

RaQualia Pharma markets and licenses intellectual property from pharmaceutical research and clinical development, aiming to discover and develop new medicines.

RaQualia Pharma Inc. outlines its privacy policy.

RaQualia Pharma Inc. secures **¥1.41 billion** in funding from **HK inno.N Corporation**. The company confirms the transaction closure, marking a significant financial injection for its operations or research initiatives. The funding follows a formal announcement by the biopharmaceutical firm.

Jan 2026MarketScreener UKNews article

HK inno.N acquires the Japanese business rights for the **K-CAP** product from **LaQualia**. The move expands HK inno.N’s presence in Japan’s medical or diagnostic technology sector, though specific applications or terms of the deal remain unstated.

Dec 2025TopDailyNews article

RaQualia Pharma Inc. secures **¥1.411 billion** in funding through a private placement of **1.56 million shares** at **¥907 per share**, with **HK inno.N Corporation** as a returning investor. The transaction, finalized via a Share Subscription Agreement, targets gross proceeds of **¥1.411 billion**, with payments due by **January 29, 2026**. The deal follows an announcement made on **December 12, 2025**.

Dec 2025MarketScreener UKNews article

RaQualia Pharma Inc. secures **¥1.029 billion** in funding from **HK inno.N Corporation**. The company finalizes the investment deal on **April 18, 2025**, marking a significant capital infusion for its operations. The funding supports RaQualia’s development pipeline, though specific use cases or projects are not disclosed in the announcement.

Apr 2025MarketScreener UKNews article